Prior to the advent of HER2-targeted therapeutics, HER2-positive disease (HER2+) was associated with a poor clinical outcome, but this dramatically changed with the development of trastuzumab and additional HER2-specific agents, especially in early HER2+ breast cancer [1–5]. Here, ERBB2 is linked to breast carcinoma.